{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T19:17:20Z","timestamp":1777317440062,"version":"3.51.4"},"reference-count":210,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PD\/BDE\/150298\/2019"],"award-info":[{"award-number":["PD\/BDE\/150298\/2019"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.ejpb.2022.05.002","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T13:22:40Z","timestamp":1652275360000},"page":"1-20","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["Spray dried powders for nasal delivery: Process and formulation considerations"],"prefix":"10.1016","volume":"176","author":[{"given":"Patr\u00edcia","family":"Henriques","sequence":"first","affiliation":[]},{"given":"Ana","family":"Fortuna","sequence":"additional","affiliation":[]},{"given":"Slavom\u00edra","family":"Doktorovov\u00e1","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.05.002_b0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejps.2013.08.029","article-title":"Bioavailability enhancement of verapamil HCl via intranasal chitosan microspheres","volume":"51","author":"Abdel Mouez","year":"2014","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119711","article-title":"Amorphous solid dispersion dry powder for pulmonary drug delivery: Advantages and challenges","author":"AboulFotouh","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2019.12.014","article-title":"Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer\u2019s disease","author":"Akel","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0020","doi-asserted-by":"crossref","DOI":"10.1080\/17425247.2017.1321634","article-title":"The design and scale-up of spray dried particle delivery systems","author":"Al-Khattawi","year":"2018","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0025","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1007\/s40265-016-0641-9","article-title":"Sumatriptan Nasal Powder: A Review in Acute Treatment of Migraine","volume":"76","author":"Al-Salama","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ejpb.2022.05.002_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/head.13737","article-title":"A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects","volume":"60","author":"Albrecht","year":"2020","journal-title":"Headache J. Head Face Pain"},{"key":"10.1016\/j.ejpb.2022.05.002_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.powtec.2021.02.031","article-title":"Designing enhanced spray dried particles for inhalation: A review of the impact of excipients and processing parameters on particle properties","author":"Alhajj","year":"2021","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0040","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ejps.2009.07.003","article-title":"Preparation of zolmitriptan\u2013chitosan microparticles by spray drying for nasal delivery","volume":"38","author":"Alhalaweh","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0045","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1208\/s12249-011-9691-1","article-title":"Surface thermodynamics of mucoadhesive dry powder formulation of zolmitriptan","volume":"12","author":"Alhalaweh","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.05.002_b0050","series-title":"Fundamentals of Early Clinical Drug Development: From Synthesis Design to Formulation","first-page":"247","article-title":"Strategies to Achieve Particle Size of Active Pharmaceutical Ingredients","author":"Am Ende","year":"2006"},{"key":"10.1016\/j.ejpb.2022.05.002_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2017.09.020","article-title":"Chemical modification of drug molecules as strategy to reduce interactions with mucus","author":"Ara\u00fajo","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6446(02)02452-2","article-title":"Permeability issues in nasal drug delivery","author":"Arora","year":"2002","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.ejpb.2022.05.002_b0065","doi-asserted-by":"crossref","DOI":"10.1208\/s12248-011-9307-4","article-title":"Absorption enhancers: Applications and advances","author":"Aungst","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2022.05.002_b0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.ejpb.2017.11.001","article-title":"Intranasal immunization with dry powder vaccines","volume":"122","author":"Bahamondez-Canas","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0075","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.colsurfa.2016.06.009","article-title":"Analysis of cohesion forces between monodisperse microparticles with rough surfaces","volume":"506","author":"Baldelli","year":"2016","journal-title":"Colloids Surfaces A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ejpb.2022.05.002_b0080","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ijpharm.2012.09.049","article-title":"Antidiuretic effect of desmopressin chimera agglomerates by nasal administration in rats","volume":"440","author":"Balducci","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0085","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0169-409X(97)00063-X","article-title":"Effects of physicochemical properties and other factors on systemic nasal drug delivery","volume":"29","author":"Behl","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0090","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10717544.2011.557787","article-title":"Design and development of nasal mucoadhesive microspheres containing tramadol HCl for CNS targeting","volume":"18","author":"Belgamwar","year":"2011","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2017.07.012","article-title":"Nasal nanovaccines","author":"Bernocchi","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0100","first-page":"Doc07","article-title":"Physiology and pathophysiology of respiratory mucosa of the nose and the paranasal sinuses","volume":"9","author":"Beule","year":"2010","journal-title":"GMS Curr. Top. Otorhinolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ejpb.2022.05.002_b0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/alr.21004","article-title":"Regional expression of epithelial MDR1\/P-glycoprotein in chronic rhinosinusitis with and without nasal polyposis","volume":"2","author":"Bleier","year":"2012","journal-title":"Int. Forum Allergy Rhinol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0110","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.brainresbull.2020.04.012","article-title":"Modulation of nose-to-brain delivery of a P-glycoprotein (MDR1) substrate model drug (quinidine) in rats","volume":"160","author":"Bors","year":"2020","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.ejpb.2022.05.002_b0115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ejps.2008.12.015","article-title":"In vitro permeation of desmopressin across rabbit nasal mucosa from liquid nasal sprays: The enhancing effect of potassium sorbate","volume":"37","author":"Bortolotti","year":"2009","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2018.05.009","article-title":"Recent advances in carrier mediated nose-to-brain delivery of pharmaceutics","author":"Bourganis","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0125","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jconrel.2012.02.028","article-title":"Particles and powders: Tools of innovation for non-invasive drug administration","volume":"161","author":"Buttini","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0130","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1002\/jps.21886","article-title":"Spray Drying Technique. I: Hardware and Process Parameters","volume":"99","author":"Cal","year":"2010","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0135","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaerosci.2018.05.008","article-title":"Flow features and micro-particle deposition in a human respiratory system during sniffing","volume":"123","author":"Calmet","year":"2018","journal-title":"J. Aerosol Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0140","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jconrel.2014.05.003","article-title":"Chitosan in nasal delivery systems for therapeutic drugs","volume":"190","author":"Casettari","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ejpb.2005.05.005","article-title":"Chitosan and poly(methyl vinyl ether-co-maleic anhydride) microparticles as nasal sustained delivery systems","volume":"61","author":"Cerchiara","year":"2005","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0150","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jcpa.2015.08.009","article-title":"A Review of the Comparative Anatomy, Histology, Physiology and Pathology of the Nasal Cavity of Rats, Mice, Dogs and Non-human Primates. Relevance to Inhalation Toxicology and Human Health Risk Assessment","volume":"153","author":"Chamanza","year":"2015","journal-title":"J. Comp. Pathol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0155","doi-asserted-by":"crossref","first-page":"215","DOI":"10.4103\/2231-4040.90876","article-title":"A review on mucoadhesive polymer used in nasal drug delivery system","volume":"2","author":"Chaturvedi","year":"2011","journal-title":"J. Adv. Pharm. Technol. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119341","article-title":"In vitro assessment of an idealized nose for nasal spray testing: Comparison with regional deposition in realistic nasal replicas","volume":"582","author":"Chen","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0165","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejps.2013.07.006","article-title":"The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA","volume":"50","author":"Chen","year":"2013","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0170","article-title":"Interaction of particles with mucosae and cell membranes","volume":"110657","author":"Chen","year":"2019","journal-title":"Colloids Surfaces B Biointerfaces"},{"key":"10.1016\/j.ejpb.2022.05.002_b0175","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/08942680152484199","article-title":"Characterization of nasal spray pumps and deposition pattern in a replica of the human nasal airway","volume":"14","author":"Cheng","year":"2001","journal-title":"J. Aerosol Med. Depos. Clear. Eff. Lung"},{"key":"10.1016\/j.ejpb.2022.05.002_b0180","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1023\/A:1013082531394","article-title":"Use of Solid Corrugated Particles to Enhance Powder Aerosol Performance","volume":"18","author":"Chew","year":"2001","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0185","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s11095-004-9020-4","article-title":"How Much Particle Surface Corrugation Is Sufficient to Improve Aerosol Performance of Powders?","volume":"22","author":"Chew","year":"2005","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijpharm.2010.08.030","article-title":"Characterization and in vitro evaluation of freeze-dried microparticles composed of granisetron\u2013cyclodextrin complex and carboxymethylcellulose for intranasal delivery","volume":"400","author":"Cho","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0195","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.ijpharm.2014.11.051","article-title":"Design of salmon calcitonin particles for nasal delivery using spray-drying and novel supercritical fluid-assisted spray-drying processes","volume":"478","author":"Cho","year":"2015","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0200","doi-asserted-by":"crossref","DOI":"10.1021\/acs.molpharmaceut.1c00366","article-title":"Structure and Fate of Nanoparticles Designed for the Nasal Delivery of Poorly Soluble Drugs","volume":"18","author":"Clementino","year":"2021","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0205","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.antiviral.2011.09.012","article-title":"Brain distribution of ribavirin after intranasal administration","volume":"92","author":"Colombo","year":"2011","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0210","unstructured":"P. Colombo, P. Santi, R. Bettini, P.L. Catellani, M. Artusi, C. Sacchetti, Powder for nasal administration of drugs,, US20050019411A1, 2005."},{"key":"10.1016\/j.ejpb.2022.05.002_b0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2021.02.012","article-title":"Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies","author":"Costa","year":"2021","journal-title":"Acta Pharm. Sin. B."},{"key":"10.1016\/j.ejpb.2022.05.002_b0220","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ijpharm.2009.06.008","article-title":"Effect on the nasal bioavailability of co-processing drug and bioadhesive carrier via spray-drying","volume":"379","author":"Coucke","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2017.12.025","article-title":"Mechanism of intranasal drug delivery directly to the brain","author":"Crowe","year":"2018","journal-title":"Life Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0230","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.antiviral.2015.09.013","article-title":"Nasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuaries","volume":"123","author":"Dalpiaz","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0235","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1002\/jps.21335","article-title":"Brain uptake of an anti-ischemic agent by nasal administration of microparticles","volume":"97","author":"Dalpiaz","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0240","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1517\/17425240903473134","article-title":"Mucoadhesion: a review of characterization techniques","volume":"7","author":"Davidovich-Pinhas","year":"2010","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2017.11.005","article-title":"Recent strategies in spray drying for the enhanced bioavailability of poorly water-soluble drugs","author":"Davis","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2022.05.002_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(01)00162-4","article-title":"Nasal vaccines","author":"Davis","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0255","doi-asserted-by":"crossref","DOI":"10.2165\/00003088-200342130-00003","article-title":"Absorption enhancers for nasal drug delivery","author":"Davis","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2022.05.002_b0260","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s13346-012-0108-9","article-title":"Nasal drug delivery devices: characteristics and performance in a clinical perspective\u2014a review","volume":"3","author":"Djupesland","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0265","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijpharm.2016.05.010","article-title":"Expression of P-glycoprotein in excised human nasal mucosa and optimized models of RPMI 2650 cells","volume":"508","author":"Dolberg","year":"2016","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0270","unstructured":"Drug Approval Package: BAQSIMI [WWW Document], n.d. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/210134Orig1s000TOC.cfm (accessed 4.14.20)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0275","unstructured":"Eli Lilly and Company, 2019. BAQSIMITM (glucagon) Nasal Powder 3 mg, the First and Only Nasally Administered Glucagon to Treat Severe Hypoglycemia in Adults and Children with Diabetes Ages Four Years and Older, Approved by FDA [WWW Document]. URL https:\/\/investor.lilly.com\/node\/41601\/pdf (accessed 5.12.20)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0280","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.carbpol.2014.02.064","article-title":"Nasal polysaccharides-glucose regulator microparticles: Optimization, tolerability and antidiabetic activity in rats","volume":"108","author":"Elmowafy","year":"2014","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.05.002_b0285","first-page":"4449","article-title":"Nanocomplexes of an insulinotropic drug: optimization, microparticle formation, and antidiabetic activity in rats","volume":"9","author":"Elmowafy","year":"2014","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ejpb.2022.05.002_b0290","unstructured":"European Medicines Agency, 2006. Guideline on the Pharmaceutical Quality of Inhalation and Nasal Products [WWW Document]. URL https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-quality-inhalation-nasal-products_en.pdf (accessed 6.19.19)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0295","unstructured":"Directive 2010\/63\/EU, 2010 - European Parliament and Council of the European Union, 2010. Directive 2010\/63\/EU of the European Parliament and of the Council of 22 September 2010 on the Protection of Animals Used for Scientific Purposes. Council of Europe, Strasbourg."},{"key":"10.1016\/j.ejpb.2022.05.002_b0300","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.ijpharm.2019.01.012","article-title":"In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation","volume":"558","author":"Fallacara","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0305","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ijpharm.2014.07.050","article-title":"Low-dose capsule filling of inhalation products: critical material attributes and process parameters","volume":"473","author":"Faulhammer","year":"2014","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0310","unstructured":"FDA, 2016. Onzetra Xsail - Sumatriptan nasal powder [WWW Document]. URL https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/206099Orig1s000TOC.cfm (accessed 6.19.19)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0315","series-title":"Pharmaceutical Sciences Encyclopedia","first-page":"1","article-title":"Nasal Powder Drug Delivery","author":"Filipovi\u0107-Gr\u010di\u0107","year":"2010"},{"key":"10.1016\/j.ejpb.2022.05.002_b0320","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ijpharm.2019.03.004","article-title":"A Design of Experiment (DoE) approach to optimise spray drying process conditions for the production of trehalose\/leucine formulations with application in pulmonary delivery","volume":"562","author":"Focaroli","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0325","unstructured":"Food and Drug Administration, 2003. Guidance for Industry Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action [WWW Document]."},{"key":"10.1016\/j.ejpb.2022.05.002_b0330","unstructured":"Food and Drug Administration, n.d. Inactive Ingredients for Approved Drug Products [WWW Document]. URL https:\/\/www.accessdata.fda.gov\/scripts\/cder\/iig\/index.cfm?event=BasicSearch.page (accessed 30.10.22)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0335","unstructured":"Food and Drug Administration, n.d. Guidance for Industry Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation [WWW Document]. 2002."},{"key":"10.1016\/j.ejpb.2022.05.002_b0340","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/17425247.2020.1714589","article-title":"A consensus research agenda for optimising nasal drug delivery","volume":"17","author":"Forbes","year":"2020","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0345","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ejpb.2014.03.004","article-title":"Intranasal delivery of systemic-acting drugs: Small-molecules and biomacromolecules","volume":"88","author":"Fortuna","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0350","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0939-6411(97)00172-0","article-title":"Spray-drying of solid lipid nanoparticles (SLN(TM))","volume":"46","author":"Freitas","year":"1998","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0355","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1248\/bpb.24.1411","article-title":"Spray-dried powders as nasal absorption enhancers of cyanocobalamin","volume":"24","author":"Garc\u00eda-Arieta","year":"2001","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2022.05.002_b0360","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1208\/pt0804081","article-title":"Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination","volume":"8","author":"Garmise","year":"2007","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.05.002_b0365","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijpharm.2005.09.013","article-title":"Nasal administration of Carbamazepine using chitosan microspheres: In vitro\/in vivo studies","volume":"307","author":"Gavini","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0370","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1002\/jps.22382","article-title":"Influence of Chitosan Glutamate on the in vivo Intranasal Absorption of Rokitamycin from Microspheres","volume":"100","author":"Gavini","year":"2011","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0375","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.ejpb.2007.05.002","article-title":"Spray-dried microspheres based on methylpyrrolidinone chitosan as new carrier for nasal administration of metoclopramide","volume":"68","author":"Gavini","year":"2008","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0380","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1211\/0022357055623","article-title":"Mucoadhesive microspheres for nasal administration of an antiemetic drug, metoclopramide: in-vitro\/ex-vivo studies","volume":"57","author":"Gavini","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0385","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11030113","article-title":"Strategies to enhance drug absorption via nasal and pulmonary routes","author":"Ghadiri","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0390","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1080\/10717544.2018.1428242","article-title":"In vivo nose-to-brain delivery of the hydrophilic antiviral ribavirin by microparticle agglomerates","volume":"25","author":"Giuliani","year":"2018","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0395","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1023\/A:1025053115583","article-title":"P-glycoprotein attenuates brain uptake of substrates after nasal instillation","volume":"20","author":"Graff","year":"2003","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2012.03.003","article-title":"Intranasal drug delivery: An efficient and non-invasive route for systemic administration - Focus on opioids","author":"Grassin-Delyle","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejpb.2022.05.002_b0405","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1021\/bm061131g","article-title":"Chitosan nanoparticle-loaded mannitol microspheres: Structure and surface characterization","volume":"8","author":"Grenha","year":"2007","journal-title":"Biomacromolecules"},{"key":"10.1016\/j.ejpb.2022.05.002_b0410","doi-asserted-by":"crossref","first-page":"806","DOI":"10.3109\/03639040903517906","article-title":"Ondansetron-loaded chitosan microspheres for nasal antiemetic drug delivery: an alternative approach to oral and parenteral routes","volume":"36","author":"Gungor","year":"2010","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0415","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3109\/10837450903148257","article-title":"Ondansetron-loaded biodegradable microspheres as a nasal sustained delivery system: In vitro\/in vivo studies","volume":"15","author":"Gungor","year":"2010","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0420","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/03639040600920309","article-title":"Development and in vitro characterization of chitosan-based microspheres for nasal delivery of promethazine","volume":"33","author":"Hafner","year":"2007","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0425","doi-asserted-by":"crossref","first-page":"E12","DOI":"10.1208\/pt070112","article-title":"Spray-dried mucoadhesive microspheres: Preparation and transport through nasal cell monolayer","volume":"7","author":"Harikarnpakdee","year":"2006","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.05.002_b0430","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-827X(02)00004-6","article-title":"Mucoadhesive microspheres containing gentamicin sulfate for nasal administration: preparation and in vitro characterization","volume":"58","author":"Has\u00e7i\u00e7ek","year":"2003","journal-title":"Farm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0435","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1208\/s12249-009-9313-3","article-title":"Effect of particle shape on dry particle inhalation: Study of flowability, aerosolization, and deposition properties","volume":"10","author":"Hassan","year":"2009","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ejpb.2022.05.002_b0440","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.powtec.2021.03.021","article-title":"Approaches for improving the flowability of high-protein dairy powders post spray drying \u2013 A review","volume":"388","author":"Hazlett","year":"2021","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0445","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jps.24541","article-title":"Amorphous Solid Dispersions: Utilization and Challenges in Drug Discovery and Development","volume":"104","author":"He","year":"2015","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0450","first-page":"2020","article-title":"Amorphous Solid Dispersions for Nasal Delivery: Development, Characterization and Aerodynamic Performance","volume":"360","author":"Henriques","year":"2020","journal-title":"AAPS PharmSci"},{"key":"10.1016\/j.ejpb.2022.05.002_b0455","series-title":"Respiratory Drug Delivery","first-page":"533","article-title":"Spray-dried Microparticles vs. Chimeral Agglomerates for Nasal Powder Delivery: Characterization and Aerodynamic Performance","author":"Henriques","year":"2020"},{"key":"10.1016\/j.ejpb.2022.05.002_b0460","series-title":"Molecular Vaccines: From Prophylaxis to Therapy - Volume 2","first-page":"717","article-title":"Nasal dry powder vaccine delivery technology","author":"Hickey","year":"2014"},{"key":"10.1016\/j.ejpb.2022.05.002_b0465","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1243\/09544119JEIM423","article-title":"Development of a nasal cast model to test medicinal nasal devices","volume":"222","author":"Hughes","year":"2008","journal-title":"Proc. Inst. Mech. Eng. H."},{"key":"10.1016\/j.ejpb.2022.05.002_b0470","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejps.2010.02.002","article-title":"Preparation and evaluation of spray-dried hyaluronic acid microspheres for intranasal delivery of fexofenadine hydrochloride","volume":"40","author":"Huh","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0475","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1080\/10837450.2019.1567762","article-title":"Spray-dried alginate microparticles for potential intranasal delivery of ropinirole hydrochloride: development, characterization and histopathological evaluation","volume":"25","author":"Hussein","year":"2020","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0480","series-title":"Advances in nasal drug delivery systems, in: Advances in Medical and Surgical Engineering","first-page":"279","author":"Hussein","year":"2020"},{"key":"10.1016\/j.ejpb.2022.05.002_b0485","unstructured":"ICH Q3C (R6) Residual solvents | European Medicines Agency [WWW Document], n.d. URL https:\/\/www.ema.europa.eu\/en\/ich-q3c-r6-residual-solvents (accessed 4.16.20)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0490","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0168-3659(02)00363-2","article-title":"Nasal drug delivery\u2014possibilities, problems and solutions","volume":"87","author":"Illum","year":"2003","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/S1359-6446(02)02529-1","article-title":"Nasal drug delivery: New developments and strategies","author":"Illum","year":"2002","journal-title":"Drug Discov. Today."},{"key":"10.1016\/j.ejpb.2022.05.002_b0500","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0378-5173(01)00708-6","article-title":"Bioadhesive starch microspheres and absorption enhancing agents act synergistically to enhance the nasal absorption of polypeptides","volume":"222","author":"Illum","year":"2001","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0505","unstructured":"Industrial Design Consultancy, n.d. Multi-Dose Dry Powder Drug Delivery [WWW Document]. URL https:\/\/www.idc.uk.com\/medical\/case-studies\/multi-dose-dry-powder-drug-delivery\/ (accessed 4.11.22)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0510","unstructured":"INFARMED, 2017. Resumo das Caracter\u00edsticas do Medicamento Pulmicort Nasal Turbohaler [WWW Document]. URL http:\/\/app7.infarmed.pt\/infomed\/download_ficheiro.php?med_id=7258&tipo_doc=rcm (accessed 6.19.19)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0515","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/jps.20484","article-title":"Anthrax vaccine powder formulations for nasal mucosal delivery","volume":"95","author":"Jiang","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0520","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0169-409X(01)00172-7","article-title":"The nose and paranasal sinuses physiology and anatomy","volume":"51","author":"Jones","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0525","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1080\/03639040801926063","article-title":"Development of a Cyclodextrin-Based Nasal Delivery System for Lorazepam","volume":"34","author":"Jug","year":"2008","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0530","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jpba.2017.06.072","article-title":"An overview of in vitro dissolution\/release methods for novel mucosal drug delivery systems","volume":"147","author":"Jug","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2022.05.002_b0535","first-page":"2","article-title":"Spray Dried Formulations for Nasal Applications - Challenges and Opportunities in Filling and Drug Delivery","author":"Juptner","year":"2018","journal-title":"Respir. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0540","article-title":"Spray dried powders for nasal application - Influence of particle morphology and filling process on aerosol generation","volume":"32","author":"J\u00fcptner","year":"2019","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0545","article-title":"Spray dried formulations for inhalation\u2014meaningful characterisation of powder properties","volume":"12","author":"J\u00fcptner","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0550","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1080\/07373937.2018.1545783","article-title":"Spray-dried nanoparticle-loaded pectin microspheres for dexamethasone nasal delivery","volume":"37","author":"Juri\u0161i\u0107 Dukovski","year":"2019","journal-title":"Dry. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0555","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.powtec.2021.08.010","article-title":"Effect of moisture content on flowability: Angle of repose, tilting angle, and Hausner ratio","volume":"393","author":"Kalman","year":"2021","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2009.06.007","article-title":"Application of chitosan microspheres for nasal delivery of vaccines","author":"Kang","year":"2009","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0565","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.msec.2015.11.028","article-title":"PLGA\/DPPC\/trimethylchitosan spray-dried microparticles for the nasal delivery of ropinirole hydrochloride: in vitro, ex vivo and cytocompatibility assessment","volume":"59","author":"Karavasili","year":"2016","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.ejpb.2022.05.002_b0570","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ejps.2018.07.059","article-title":"Chemical cross-linking: A feasible approach to prolong doxylamine\/pyridoxine release from spray-dried chitosan microspheres","volume":"123","author":"Katsarov","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0575","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1515\/folmed-2017-0037","article-title":"Optimization of Chitosan Microspheres Spray Drying via 32 Full Factorial Design","volume":"59","author":"Katsarov","year":"2017","journal-title":"Folia Med. (Plovdiv)"},{"key":"10.1016\/j.ejpb.2022.05.002_b0580","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jconrel.2017.09.001","article-title":"Progress in brain targeting drug delivery system by nasal route","volume":"268","author":"Khan","year":"2017","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0585","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(97)00067-7","article-title":"Nasal delivery systems and their effect on deposition and absorption","author":"Kublik","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0590","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.jddst.2015.12.004","article-title":"In vitro, ex vivo and in vivo performance of chitosan-based spray-dried nasal mucoadhesive microspheres of diltiazem hydrochloride","volume":"31","author":"Kulkarni","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0595","first-page":"21","article-title":"Advances in nasal trans-mucosal drug delivery","author":"Kushwaha","year":"2011","journal-title":"J. Appl. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0600","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120994","article-title":"Progress in nasal drug delivery systems","volume":"607","author":"Laffleur","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0605","article-title":"In vitro \u2013 in vivo correlation of intranasal drug deposition","author":"Le Guellec","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2017.09.018","article-title":"Physicochemical properties of mucus and their impact on transmucosal drug delivery","author":"Leal","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0615","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s13318-013-0171-8","article-title":"Pharmacokinetic evaluation of formulated levodopa methyl ester nasal delivery systems","volume":"39","author":"Lee","year":"2014","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2022.05.002_b0620","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.tiv.2013.06.018","article-title":"The Slug Mucosal Irritation (SMI) assay: a tool for the evaluation of nasal discomfort","volume":"27","author":"Lenoir","year":"2013","journal-title":"Toxicol. In Vitro"},{"key":"10.1016\/j.ejpb.2022.05.002_b0625","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1002\/jps.23955","article-title":"Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles\/nanoparticles for targeted pulmonary delivery as dry powder inhalers","volume":"103","author":"Li","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0630","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jconrel.2003.09.019","article-title":"Liposomes and disaccharides as carriers in spray-dried powder formulations of superoxide dismutase","volume":"94","author":"Lo","year":"2004","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118813","article-title":"Nasal route for vaccine and drug delivery: Features and current opportunities","author":"Lobaina Mato","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0640","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.3390\/pharmaceutics13071079","article-title":"In Vitro Evaluation of Nasal Aerosol Depositions: An Insight for Direct Nose to Brain Drug Delivery","volume":"13","author":"Maaz","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0645","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1248\/cpb.57.388","article-title":"Gellan gum based microparticles of metoclopromide hydrochloride for intranasal delivery: Development and evaluation","volume":"57","author":"Mahajan","year":"2009","journal-title":"Chem. Pharm. Bull."},{"key":"10.1016\/j.ejpb.2022.05.002_b0650","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1080\/10837450802585286","article-title":"Nasal administration of ondansetron using a novel microspheres delivery system","volume":"14","author":"Mahajan","year":"2009","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0655","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/02652040500098960","article-title":"Spray-dried chitosan\/ethylcellulose microspheres for nasal drug delivery: Swelling study and evaluation of in vitro drug release properties","volume":"22","author":"Martinac","year":"2005","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2022.05.002_b0660","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ijpharm.2004.07.044","article-title":"Development and bioadhesive properties of chitosan-ethylcellulose microspheres for nasal delivery","volume":"291","author":"Martinac","year":"2005","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118635","article-title":"Strategies to facilitate or block nose-to-brain drug delivery","author":"Martins","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0670","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1021\/js960500j","article-title":"Nasal Absorption of Dihydroergotamine from Liquid and Powder Formulations in Rabbits","volume":"86","author":"Marttin","year":"1997","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0675","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-409X(97)00059-8","article-title":"Nasal mucociliary clearance as a factor in nasal drug delivery","volume":"29","author":"Marttin","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0680","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2006.08.004","article-title":"Improved nasal absorption of salmon calcitonin by powdery formulation with N-acetyl-l-cysteine as a mucolytic agent","volume":"115","author":"Matsuyama","year":"2006","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0685","doi-asserted-by":"crossref","DOI":"10.1016\/S0169-409X(98)00054-4","article-title":"Cyclodextrins in nasal drug delivery","author":"Merkus","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0690","doi-asserted-by":"crossref","first-page":"923","DOI":"10.3109\/10717544.2014.923064","article-title":"Brain targeting by intranasal drug delivery (INDD): a combined effect of trans-neural and para-neuronal pathway","volume":"23","author":"Mustafa","year":"2016","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0695","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(97)00058-6","article-title":"Anatomy, physiology and function of the nasal cavities in health and disease","volume":"29","author":"Mygind","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0700","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2174\/156720112800234503","article-title":"Preparation and characterization of spray-dried mucoadhesive microspheres of ketorolac for nasal administration","volume":"9","author":"Nagda","year":"2012","journal-title":"Curr. Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0705","unstructured":"N. Neves, M. Braga, E. Costa, Statistical Approach on the Key Parameters of a Dosator-based Capsule Filling Process of Carrier-based and Spray Dried Powders: Impact on the In Vitro Aerodynamic Performance, in: Respiratory Drug Delivery 2019 Volume 2, 2019, pp. 295\u2013300."},{"key":"10.1016\/j.ejpb.2022.05.002_b0710","series-title":"Pharmaceutical Amorphous Solid Dispersions","author":"Newman","year":"2015"},{"key":"10.1016\/j.ejpb.2022.05.002_b0715","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v21.i1.20","article-title":"Drug Delivery to the Nasal Cavity. In Vitro and In Vivo Assessment","volume":"21","author":"Newman","year":"2004","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"key":"10.1016\/j.ejpb.2022.05.002_b0720","doi-asserted-by":"crossref","first-page":"105115","DOI":"10.1016\/j.ejps.2019.105115","article-title":"Development, characterisation and nasal deposition of melatonin-loaded pectin\/hypromellose microspheres","volume":"141","author":"Ni\u017ei\u0107","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0725","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/pharmaceutics13060795","article-title":"A Dry Powder Platform for Nose-to-Brain Delivery of Dexamethasone: Formulation Development and Nasal Deposition Studies","volume":"13","author":"Nodilo","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0730","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.3390\/molecules14093754","article-title":"Nasal Delivery of High Molecular Weight Drugs","volume":"14","author":"Ozsoy","year":"2009","journal-title":"Molecules"},{"key":"10.1016\/j.ejpb.2022.05.002_b0735","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/02652048.2011.630106","article-title":"Formulation, optimization and evaluation of spray-dried mucoadhesive microspheres as intranasal carriers for Valsartan","volume":"29","author":"Pardeshi","year":"2012","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ejpb.2022.05.002_b0740","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2020.170296","article-title":"Glucagon-based therapy: Past, present and future","author":"Patil","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.ejpb.2022.05.002_b0745","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0169-409X(97)00069-0","article-title":"Microspheres as nasal drug delivery systems","volume":"29","author":"Pereswetoff-Morath","year":"1998","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0750","doi-asserted-by":"crossref","first-page":"288","DOI":"10.18433\/J3NC79","article-title":"Intranasal drug delivery: how, why and what for?","volume":"12","author":"Pires","year":"2009","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.jconrel.2017.11.047","article-title":"Nanosystems in nose-to-brain drug delivery: A review of non-clinical brain targeting studies","author":"Pires","year":"2018","journal-title":"J. Control. Release."},{"key":"10.1016\/j.ejpb.2022.05.002_b0760","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jpba.2011.05.008","article-title":"Analysis of co-spray-dried meloxicam\u2013mannitol systems containing crystalline microcomposites","volume":"56","author":"Pom\u00e1zi","year":"2011","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.ejpb.2022.05.002_b0765","article-title":"Intranasal Glucagon","author":"Pontiroli","year":"2019","journal-title":"J. Pak. Med. Assoc."},{"key":"10.1016\/j.ejpb.2022.05.002_b0770","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1932296814557518","article-title":"Intranasal glucagon: a promising approach for treatment of severe hypoglycemia","volume":"9","author":"Pontiroli","year":"2015","journal-title":"J. Diabetes Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0775","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1080\/03639045.2017.1321659","article-title":"Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery","volume":"43","author":"Pozzoli","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2005.10.049","article-title":"Influence of deposition and spray pattern of nasal powders on insulin bioavailability","volume":"310","author":"Pringels","year":"2006","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0785","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120728","article-title":"Spray-dried mucoadhesive microparticles based on S-protected thiolated hydroxypropyl-\u03b2-cyclodextrin for budesonide nasal delivery","volume":"603","author":"Racaniello","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0790","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics10040206","article-title":"The role of combined penetration enhancers in nasal microspheres on in vivo drug bioavailability","volume":"10","author":"Rassu","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0795","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1002\/jps.21751","article-title":"New chitosan derivatives for the preparation of rokitamycin loaded microspheres designed for ocular or nasal administration","volume":"98","author":"Rassu","year":"2009","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0800","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jconrel.2015.01.025","article-title":"Solid microparticles based on chitosan or methyl-\u03b2-cyclodextrin: A first formulative approach to increase the nose-to-brain transport of deferoxamine mesylate","volume":"201","author":"Rassu","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0805","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijpharm.2018.10.029","article-title":"Advanced formulations for intranasal delivery of biologics","volume":"553","author":"Rohrer","year":"2018","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0810","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S1773-2247(04)50083-7","article-title":"Chimeral agglomerates of microparticles for the administration of caffeine nasal powders","volume":"14","author":"Russo","year":"2004","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0815","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/jps.20604","article-title":"Primary Microparticles and Agglomerates of Morphine for Nasal Insufflation","volume":"95","author":"Russo","year":"2006","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0820","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0378-5173(02)00177-1","article-title":"Caffeine microparticles for nasal administration obtained by spray drying","volume":"242","author":"Sacchetti","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0825","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ijpharm.2019.02.026","article-title":"How to characterize a nasal product. The state of the art of in vitro and ex vivo specific methods","volume":"561","author":"Salade","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0830","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejpb.2018.06.011","article-title":"Chitosan-coated liposome dry-powder formulations loaded with ghrelin for nose-to-brain delivery","volume":"129","author":"Salade","year":"2018","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0835","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13346-012-0086-y","article-title":"Microparticles based on chitosan\/pectin polyelectrolyte complexes for nasal delivery of tacrine hydrochloride","volume":"3","author":"Saladini","year":"2013","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0840","doi-asserted-by":"crossref","DOI":"10.4155\/tde-2019-0086","article-title":"Nasal formulations for drug administration and characterization of nasal preparations in drug delivery","volume":"11","author":"Scherlie\u00df","year":"2020","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0845","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.powtec.2007.03.046","article-title":"Amino acid-modified spray-dried powders with enhanced aerosolisation properties for pulmonary drug delivery","volume":"178","author":"Seville","year":"2007","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0850","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2133\/dmpk.DMPK-10-RG-108","article-title":"Nasal delivery of P-gp substrates to the brain through the nosebrain pathway","volume":"26","author":"Shingaki","year":"2011","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ejpb.2022.05.002_b0855","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.addr.2006.07.010","article-title":"Particle engineering techniques for inhaled biopharmaceuticals","volume":"58","author":"Shoyele","year":"2006","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0860","unstructured":"M.F. Silva, D.A. Fernandes, M. Braga, A. Eloy, J. Marques, M.L. Corvo, E. Costa, Nasal dry powder delivery: Implementing a spray drying process for an API-independent formulation. DDL2018, 2018."},{"key":"10.1016\/j.ejpb.2022.05.002_b0865","series-title":"Respiratory Drug Delivery 2019 Volume 2","first-page":"307","article-title":"Implementing a spray drying process and aerodynamic performance characterization for nasal dry powder formulations","author":"Silva","year":"2019"},{"key":"10.1016\/j.ejpb.2022.05.002_b0870","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.addr.2015.12.010","article-title":"Spray drying formulation of amorphous solid dispersions","volume":"100","author":"Singh","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0875","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/pharmaceutics10010034","article-title":"Surface-Modified Nanocarriers for Nose-to-Brain Delivery: From Bioadhesion to Targeting","volume":"10","author":"Sonvico","year":"2018","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0880","doi-asserted-by":"crossref","DOI":"10.1016\/j.progpolymsci.2014.07.010","article-title":"Mucoadhesive polymers in the design of nano-drug delivery systems for administration by non-parenteral routes: A review","author":"Sosnik","year":"2014","journal-title":"Prog. Polym. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0885","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2004.03.010","article-title":"A novel spray-drying technique to produce low density particles for pulmonary delivery","volume":"278","author":"Steckel","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0890","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1080\/03639040802395185","article-title":"The effect of chitosan molecular weight on the characteristics of spray-dried methotrexate-loaded chitosan microspheres for nasal administration","volume":"35","author":"Sun","year":"2009","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0895","doi-asserted-by":"crossref","first-page":"894","DOI":"10.3109\/10717544.2013.860205","article-title":"Bioavailability enhancement of ondansetron after nasal administration of Caesalpinia pulcherrima- based microspheres","volume":"22","author":"Suryawanshi","year":"2015","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ejpb.2022.05.002_b0900","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cep.2012.06.004","article-title":"Supercritical fluids for pharmaceutical particle engineering: Methods, basic fundamentals and modelling","volume":"60","author":"Tabernero","year":"2012","journal-title":"Chem. Eng. Process. Process Intensif."},{"key":"10.1016\/j.ejpb.2022.05.002_b0905","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2147\/MDER.S130900","article-title":"Breath-powered sumatriptan dry nasal powder: an intranasal medication delivery system for acute treatment of migraine","volume":"11","author":"Tepper","year":"2018","journal-title":"Med. Devices Evid. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0910","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jconrel.2018.10.020","article-title":"Intranasal immunization with aluminum salt-adjuvanted dry powder vaccine","volume":"292","author":"Thakkar","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejpb.2022.05.002_b0915","article-title":"Flurbiprofen Sodium Microparticles and Soft Pellets for Nose-to-Brain Delivery: Serum and Brain Levels in Rats after Nasal Insufflation","volume":"120827","author":"Tiozzo Fasiolo","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b0920","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/1061186X.2019.1574300","article-title":"Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer\u2019s disease","volume":"27","author":"Tiozzo Fasiolo","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejpb.2022.05.002_b0925","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ejps.2017.09.027","article-title":"Opportunity and challenges of nasal powders: Drug formulation and delivery","volume":"113","author":"Tiozzo Fasiolo","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0930","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2014.10.002","article-title":"Live attenuated and inactivated viral vaccine formulation and nasal delivery: Potential and challenges","author":"Tlaxca","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0935","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/pharmaceutics13030385","article-title":"Nasal Powder Formulations: In-Vitro Characterisation of the Impact of Powders on Nasal Residence Time and Sensory Effects","volume":"13","author":"Trenkel","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejpb.2022.05.002_b0940","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.powtec.2016.01.042","article-title":"Carrier-based dry powder formulation for nasal delivery of vaccines utilizing BSA as model drug","volume":"292","author":"Trows","year":"2016","journal-title":"Powder Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b0945","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.annemergmed.2016.08.450","article-title":"Optimal Volume of Administration of Intranasal Midazolam in Children: A Randomized Clinical Trial","volume":"69","author":"Tsze","year":"2017","journal-title":"Ann. Emerg. Med."},{"key":"10.1016\/j.ejpb.2022.05.002_b0950","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.addr.2005.07.009","article-title":"Nasal mucoadhesive drug delivery: Background, applications, trends and future perspectives","volume":"57","author":"Ugwoke","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejpb.2022.05.002_b0955","unstructured":"Unit-Dose \/ Bidose systems - UDS | Aptar Pharma [WWW Document], n.d. URL https:\/\/pharma.aptar.com\/en-us\/dispensing-solutions\/uds.html (accessed 5.14.20)."},{"key":"10.1016\/j.ejpb.2022.05.002_b0960","doi-asserted-by":"crossref","unstructured":"United States Pharmacopeia (USP), \u30081112\u3009 Application of Water Activity Determination to Nonsterile Pharmaceutical Products. The United States Pharmacopeial Convention, 2022. doi:10.31003\/USPNF_M402_01_01.","DOI":"10.31003\/USPNF_M402_01_01"},{"key":"10.1016\/j.ejpb.2022.05.002_b0965","unstructured":"USP-NF \u3008601\u3009 Inhalation and Nasal Drug Products: Aerosols, Sprays, and Powders\u2014Performance Quality Tests, n.d. , in: United States Pharmacopeia 43-NF38 2S."},{"key":"10.1016\/j.ejpb.2022.05.002_b0970","doi-asserted-by":"crossref","DOI":"10.1007\/s11095-007-9475-1","article-title":"Pharmaceutical particle engineering via spray drying","author":"Vehring","year":"2008","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejpb.2022.05.002_b0975","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.powtec.2013.06.038","article-title":"Fundamental analysis of particle formation in spray drying","volume":"247","author":"Vicente","year":"2013","journal-title":"Powder Technol."},{"issue":"2","key":"10.1016\/j.ejpb.2022.05.002_b0980","first-page":"34","article-title":"Applying Quality by Design to spray drying-The role of empirical and mechanistic modeling","volume":"31","author":"Vicente","year":"2013","journal-title":"Chim. Oggi-Chem. Today"},{"key":"10.1016\/j.ejpb.2022.05.002_b0985","series-title":"Developing Solid Oral Dosage Forms","first-page":"793","article-title":"Formulation, Process Development, and Scale-Up: Spray-Drying Amorphous Solid Dispersions for Insoluble Drugs","author":"Vig","year":"2017"},{"key":"10.1016\/j.ejpb.2022.05.002_b0990","doi-asserted-by":"crossref","DOI":"10.1002\/jps.23998","article-title":"Next generation drying technologies for pharmaceutical applications","author":"Walters","year":"2014","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b0995","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1205\/026387699525846","article-title":"Spray dried products-characterization of particle morphology","volume":"77","author":"Walton","year":"1999","journal-title":"Chem. Eng. Res. Des."},{"key":"10.1016\/j.ejpb.2022.05.002_b1000","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S1773-2247(13)50052-9","article-title":"Particle engineering technologies for improving the delivery of peptide and protein drugs","volume":"23","author":"Wan","year":"2013","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b1005","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.carbpol.2012.08.084","article-title":"Characterizations and microsphere formulation of polysaccharide from the marine clam (Mactra veneriformis)","volume":"92","author":"Wang","year":"2013","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.05.002_b1010","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/jps.22742","article-title":"Stable Dry Powder Formulation for Nasal Delivery of Anthrax Vaccine","volume":"101","author":"Wang","year":"2012","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b1015","article-title":"Leucine Enhances the Dispersibility of Trehalose-Containing Spray-Dried Powders on Exposure to a High-Humidity Environment","volume":"120561","author":"Wang","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejpb.2022.05.002_b1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.jddst.2016.05.003","article-title":"Formulation and device design to increase nose to brain drug delivery","author":"Warnken","year":"2016","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.ejpb.2022.05.002_b1025","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.xphs.2016.05.017","article-title":"Neuroprotective Effects of Engineered Polymeric Nasal Microspheres Containing Hydroxypropyl-\u03b2-cyclodextrin on \u03b2-Amyloid (1\u201342)\u2013Induced Toxicity","volume":"105","author":"Yalcin","year":"2016","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ejpb.2022.05.002_b1030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.carbpol.2017.01.044","article-title":"Formulation of olfactory-targeted microparticles with tamarind seed polysaccharide to improve nose-to-brain transport of drugs","volume":"163","author":"Yarragudi","year":"2017","journal-title":"Carbohydr. Polym."},{"key":"10.1016\/j.ejpb.2022.05.002_b1035","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1248\/cpb.56.1645","article-title":"Preparation of a Dispersible PEGylate Nanostructured Lipid Carriers (NLC) Loaded with 10-Hydroxycamptothecin by Spray-Drying","volume":"56","author":"Zhang","year":"2008","journal-title":"Chem. Pharm. Bull. (Tokyo)"},{"key":"10.1016\/j.ejpb.2022.05.002_b1040","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1208\/s12248-012-9325-x","article-title":"Pharmacokinetic Evaluation of Intranasally Administered Vinyl Polymer-Coated Lorazepam Microparticles in Rabbits","volume":"14","author":"Zhao","year":"2012","journal-title":"AAPS J."},{"key":"10.1016\/j.ejpb.2022.05.002_b1045","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.ejps.2018.10.026","article-title":"Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches","volume":"127","author":"Ziaee","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"issue":"3","key":"10.1016\/j.ejpb.2022.05.002_bib1046","article-title":"Benchmarking of particle engineering technologies for nasal powder manufacture","volume":"34","author":"Henriques","year":"2021","journal-title":"Journal of Aerosol Medicine and Pulmonary Drug Delivery"}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112200090X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S093964112200090X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:46:31Z","timestamp":1760546791000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S093964112200090X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":210,"alternative-id":["S093964112200090X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.05.002","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spray dried powders for nasal delivery: Process and formulation considerations","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.05.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}